Skip to content

Effects of Oxytocin on Emotion Recognition and Response Inhibition

Effects of Oxytocin on Emotion Recognition and Response Inhibition

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02350946
Enrollment
40
Registered
2015-01-30
Start date
2015-01-31
Completion date
2017-01-31
Last updated
2015-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The Impact of Oxytocin on Social Cognition

Brief summary

The purpose of this study is to shed light on the basic neurobiological mechanisms which underlie social information processing in healthy men. More specifically, we intend to examine whether a person's social competence level is related to the patterns of neural activity and his visual search strategies during evaluation of social scenes. Furthermore, it will be assessed whether an oxytocin-driven increase in activity in brain areas relevant to the task will facilitate social information processing and thus enhance task performance. Additionally it will be examined whether oxytocin can facilitate response inhibition in an emotional context.

Interventions

DRUGOxytocin
DRUGPlacebo

Sponsors

RWTH Aachen University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* MRI- eligibility * Subject's ability to fully grasp the type, scope and individual consequences of the study * Willingness to participate in and comply with the study procedures as indicated by signing the dated informed consent form

Exclusion criteria

* Left-handedness * Smoking * Regular intake of medication * Hypersensitivity towards oxytocin or a chemically similar substance * Current or previous neurological or psychiatric disorder * Nose surgery or chronic sinus infection * Any somatic disorder that may interfere with the experimental procedures, affect the outcome measures or pose a risk for the participant during performance of the experiment

Design outcomes

Primary

MeasureTime frameDescription
BOLD response during emotion recognition in contrast with a corresponding control condition.(Day 1: oxytocin, Day: 14:placebo, or vice versa [counterbalanced])In the Social Detection Task, subjects' brain activity when viewing social scenes will be compared to corresponding control scenes in which no people are shown. In the GoNoGo Task several emotional conditions will be compared to a neutral control condition.
BOLD response during response inhibition (Emotional Go/ Nogo) in contrast with a corresponding control condition.(Day 1: oxytocin, Day: 14:placebo, or vice versa [counterbalanced])Brain activation during NoGo trials will be compared to brain activation during Go trials from the same emotional condition.

Secondary

MeasureTime frameDescription
Serum levels of Cortisol(Day 1: oxytocin, Day: 14:placebo, or vice versa [counterbalanced])
Total length of fixations on areas of interest (AOIs) assessed via eye-tracking(Day 1: oxytocin, Day: 14:placebo, or vice versa [counterbalanced])In the SoDeTa stimulus set, faces, arms and hands were defined as 1st order AOIs and remaining parts of the body as 2nd order AOIs. In the GoNoGo task, for each stimulus, the eye region of the face was chosen as AOI.
Serum levels of Oxytocin(Day 1: oxytocin, Day: 14:placebo, or vice versa [counterbalanced])
Percentage of correct responses in an emotion recognition paradigm (Social Detection Task) and a response inhibition task (Emotional Go/Nogo).(Day 1: oxytocin, Day: 14:placebo, or vice versa [counterbalanced])
Response time in an emotion recognition paradigm (Social Detection Task) and a response inhibition task (Emotional Go/Nogo).(Day 1: oxytocin, Day: 14:placebo, or vice versa [counterbalanced])
Number of fixations on areas of interest (AOIs) assessed via eye-tracking(Day 1: oxytocin, Day: 14:placebo, or vice versa [counterbalanced])In the SoDeTa stimulus set, faces, arms and hands were defined as 1st order AOIs and remaining parts of the body as 2nd order AOIs. In the GoNoGo task, for each stimulus, the eye region of the face was chosen as AOI.
Serum levels of Prolaktin(Day 1: oxytocin, Day: 14:placebo, or vice versa [counterbalanced])

Countries

Germany

Contacts

Primary ContactLisa Deuse
ldeuse@ukaachen.de02418085692
Backup ContactSarah E Groppe
sgroppe@ukaachen.de02418037151

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026